Variation in antipsychotic treatment choice across US nursing homes

Journal of Clinical Psychopharmacology

Volumn 32, Issue 1, 2012, Pages 11-17

  Huybrechts, Krista F ^a,b   Rothman, Kenneth J ^b,c   Brookhart, M Alan ^d   Silliman, Rebecca A ^b,e   Crystal, Stephen ^f   Gerhard, Tobias ^f   Schneeweiss, Sebastian ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

^c RTI HEALTH SOLUTIONS   (United States)

^d IL   (United States)

^e BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f RUTGERS UNIVERSITY   (United States)

Author keywords

antipsychotics; nursing homes; treatment choice variation

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CHLORPROMAZINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE;

AGED; ANXIETY; ARTICLE; BEHAVIOR DISORDER; COGNITION; DELIRIUM; DELUSION; DEMENTIA; DEPRESSION; DRUG CHOICE; DRUG USE; FEMALE; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; MEDICAL PRACTICE; NURSING HOME; PRESCRIPTION; PRIORITY JOURNAL; QUALITY CONTROL; UNITED STATES;

AGED; ANTIPSYCHOTIC AGENTS; COHORT STUDIES; COST-BENEFIT ANALYSIS; DEMENTIA; DRUG UTILIZATION; FEMALE; HOMES FOR THE AGED; HUMANS; INSURANCE CLAIM REVIEW; MALE; MEDICAID; MEDICARE; MIDDLE AGED; NURSING HOMES; PHYSICIAN'S PRACTICE PATTERNS; QUALITY IMPROVEMENT; UNITED STATES;

EID: 84855349950     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0b013e31823f6f46     Document Type: Article

References (32)

1. Beers M, Avorn J, Soumerai S, et al. Psychoactive medication use in intermediate-care facility residents. JAMA. 1988;260:3016-3020. (Pubitemid 19003116)
2. Ray WA, Federspiel CF, Schaffner W. A study of antipsychotic drug use in nursing homes: epidemiologic evidence suggesting misuse. Am J Public Health. 1980;70:485-491. (Pubitemid 10098089)
3. Shorr RI, Fought RL, Ray WA. Changes in antipsychotic drug use in nursing homes during implementation of the OBRA-87 regulations. JAMA. 1994;271:358-362. (Pubitemid 24037909)
4. Garrard J, Chen V, Dowd B. The impact of the 1987 federal regulations on the use of psychotropic drugs in Minnesota nursing homes. Am J Public Health. 1995;85:771-776.
5. Ray WA, Taylor JA, Meador KG, et al. Reducing antipsychotic drug use in nursing homes: a controlled trial of provider education. Arch Int Med. 1993;153:713-721. (Pubitemid 23094850)
6. Avorn J, Soumerai S, Everitt D, et al. A randomized trial of a program to reduce the use of psychoactive drugs in nursing homes. N Engl J Med. 1992;327:168-173.
7. Chen Y, Briesacher B, Field T, et al. Unexplained variation across US nursing homes in antipsychotic prescribing rates. Arch Int Med. 2010;170:89-95.
8. Liperoti R, Mor V, Lapane KL, et al. The use of atypical antipsychotics in nursing homes. J Clin Psychiatry. 2003;64:1106-1112. (Pubitemid 37158258)
9. Rochon PA, Stukel TA, Bronskill SE, et al. Variation in nursing home antipsychotic prescribing rates. Arch Int Med. 2007;167:676-683. (Pubitemid 46598460)
10. Crystal S, Olfson M, Huang C, et al. Broadened use of atypical antipsychotics: safety, effectiveness, and policy challenges. Health Affairs. 2009;28:770-781.
11. Giron MST, Forsell Y, Bernsten C, et al. Psychotropic drug use in elderly people with and without dementia. Int J Geriatr Psychiatry. 2001;16:900-906. (Pubitemid 32926775)
12. Jeste DV, Blazer D, Casey D, et al. ACNP white paper: update on use of antipsychotic drugs in elderly persons with dementia. Neuropsychopharmacology. 2007;33:957-970. (Pubitemid 351367549)
13. FDA Public Health Advisory: Deaths with Antipsychotics in Elderly Patients with Behavioral Disturbances. Available at: http://www.fda.gov/Drugs/ DrugSafety/PublicHealthAdvisories/ucm053171.htm]. Accessed May 3, 2010.
14. FDA: Information for Healthcare ProfessionalsVAntipsychotics. Available at: http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ucm124830.htm. Accessed May 3, 2010.
15. Health Canada (Ottawa): Health Canada advises consumers about important safety information on atypical antipsychotic drugs and dementia. Available at: http://www.hc-sc.gc.ca/ahc-asc/media/advisories-avis/-2005/2005-63-eng.php. Accessed May 3, 2010.
16. Schneeweiss S, Setoguchi S, Brookhart A, et al. Risk of death associated with the use of conventional versus atypical antipsychotic drugs among elderly patients. Can Med Assoc J. 2007;176:627-632. (Pubitemid 46426056)
17. Gill SS, Bronskill SE, Normand S-LT, et al. Antipsychotic drug use and mortality in older adults with dementia. Ann Intern Med. 2007;146:775-786. (Pubitemid 351650498)
18. Wang PS, Schneeweiss S, Avorn J, et al. Risk of death in elderly users of conventional vs. atypical antipsychotic medications. N Engl J Med. 2005;353:2335-2341. (Pubitemid 41713745)
19. Hughes CM, Lapane KL, Mor V. Influence of facility characteristics on use of antipsychotic medications in nursing homes. Med Care. 2000;38:1164-1173.
20. Gruneir A, Lapane KL. It is time to assess the role of organizational culture in nursing home prescribing patterns. Arch Intern Med. 2008;168:238-239. (Pubitemid 351185898)
21. Liperoti R, Gambassi G, Lapane KL, et al. Conventional and atypical antipsychotics and the risk of hospitalization for ventricular arrhythmias or cardiac arrest. Arch Intern Med. 2005;165:696-701. (Pubitemid 40393155)
22. Liperoti R, Onder G, Lapane K, et al. Conventional or atypical antipsychotics and the risk of femur fracture among elderly patients: results of a case-control study. J Clin Psychiatry. 2007;68:929-934. (Pubitemid 47015494)
23. Knol W, van Marum R, Jansen P, et al. Antipsychotic drug use and risk of pneumonia in elderly people. J Am Geriatr Soc. 2008;56:661-666. (Pubitemid 351473519)
24. Rochon PA, Normand S-L, Gomes T, et al. Antipsychotic therapy and short-term serious events in older adults with dementia. Arch Intern Med. 2008;168:1090-1096. (Pubitemid 351749226)
25. Gill SS, Rochon PA, Herrmann N, et al. Atypical antipsychotic drugs and risk of ischaemic stroke: Population based retrospective cohort study. BMJ. 2005;330:445.
26. Ballard C, Hanney ML, Theodoulou M, et al. The dementia antipsychotic withdrawal trial (DART-AD): long-term follow-up of a randomised placebo-controlled trial. Lancet Neurol. 2009;8:151-157.
27. Greenland S. An introduction to instrumental variables for epidemiologists. Int J Epidemiol. 2000;29:722-729. (Pubitemid 30612241)
28. Brookhart M, Schneeweiss S. Preference-based instrumental variable methods for the estimation of treatment effect: assessing validity and interpreting results. Int J Biostat. 2007;3:1-23 (Article 14).
29. Snowden M, McCormick W, Russo J, et al. Validity and responsiveness of the minimum data set. J Am Geriatr Soc. 1999;47:1000-1004. (Pubitemid 29380495)
30. Schemper M. Predictive accuracy and explained variation. Stat Med. 2003;22:2299-2308. (Pubitemid 36926941)
31. Hofer TP, Hayward RA, Greenfield S, et al. The unreliability of individual physician WReport CardsW for assessing the costs and quality of care of a chronic disease. JAMA. 1999;281:2098-2105. (Pubitemid 29264688)
32. Brookhart M, Solomon D, Wang P, et al. Explained variation in a model of therapeutic decision making is partitioned across patient, physician, and clinic factors. J Clin Epidemiol. 2006;59:18-25. (Pubitemid 41797471)